F S&P 500
5,124.00 +17.50 (+0.34%) F Dow Jones
38,772.00 +46.00 (+0.12%) F Nasdaq
17,727.75 +121.00 (+0.69%) E-mini Russell 2000 Index Futur
2,017.40 +2.50 (+0.12%) Petróleo
83.44 +0.08 (+0.10%) Oro
2,340.20 -1.90 (-0.08%)
REGENXBIO Inc. (RGNX)
Fuera de horario:
REGENXBIO Inc.
9804 Medical Center Drive
Rockville, MD 20850
United States
240 552 8181
https://www.regenxbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 344
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kenneth T. Mills | President, CEO & Director | 1M | 720.99k | 1975 |
| Mr. Vittal K. Vasista | Executive VP & CFO | 666.5k | 573.3k | 1968 |
| Mr. Curran M. Simpson M.S. | Executive VP & COO | 698.6k | N/D | 1962 |
| Dr. Olivier Danos Ph.D. | Executive VP & Chief Scientific Officer | 778.85k | N/D | 1958 |
| Dr. Stephen Pakola M.D. | Executive VP & Chief Medical Officer | 674.05k | N/D | 1969 |
| Mr. Patrick J. Christmas II, J.D. | Executive VP & Chief Legal Officer | 1.11M | 1.29M | 1971 |
| Ms. Shiva G. Fritsch | Chief Communications & People Officer | N/D | N/D | N/D |
| Dr. Laura A. Coruzzi J.D., Ph.D. | Executive Vice President of Intellectual Property | N/D | N/D | 1954 |
| Dr. Ram Palanki Pharm.D. | Executive VP of Commercial Strategy & Operations | N/D | N/D | 1977 |
Descripción
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de REGENXBIO Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 2; Junta: 8; Derechos del accionista: 8; Compensación: 8.
